WuXi AppTec Co Ltd
SSE:603259
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
WuXi AppTec Co Ltd
Pre-Tax Income
WuXi AppTec Co Ltd
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
WuXi AppTec Co Ltd
SSE:603259
|
Pre-Tax Income
¥23.9B
|
CAGR 3-Years
31%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
J
|
Joinn Laboratories China Co Ltd
SSE:603127
|
Pre-Tax Income
¥337.5m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Pre-Tax Income
¥1.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Pre-Tax Income
¥7.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Pre-Tax Income
¥1.3B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
19%
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Pre-Tax Income
¥1.7B
|
CAGR 3-Years
107%
|
CAGR 5-Years
122%
|
CAGR 10-Years
N/A
|
|
WuXi AppTec Co Ltd
Glance View
In the bustling corridors of global pharmaceuticals, WuXi AppTec Co Ltd. emerges as a vital bridge between expansive scientific potential and the practical demands of drug development. Founded in China, WuXi AppTec began its journey by transforming itself into a leading provider of R&D and manufacturing services to the pharmaceutical, biotech, and healthcare industries. With a broad portfolio that spans from the initial stages of drug discovery to the intricate processes of commercial production, WuXi AppTec offers an integrated platform to its clients. This platform allows global pharmaceutical companies, fledgling biotech firms, and even academic institutions to streamline their research initiatives, reduce development timelines, and ultimately bring therapeutic innovations to the market more efficiently. The company's business model thrives on its "one-stop-shop" approach, which is comprised of client-tailored solutions that address every stage of the drug development lifecycle. WuXi generates revenue through a variety of services, including laboratory testing, clinical trial support, and large-scale manufacturing. By leveraging its comprehensive capabilities in chemistry, biologics, and genomics, it successfully caters to a diversified clientele, ensuring sustainability through a steady stream of contract-based income. With an emphasis on advanced technologies and a global footprint that covers North America, Europe, and Asia, WuXi AppTec stands as a crucial ally to innovators ardently seeking to overcome the challenges of modern medicine by expediting the path from ‘concept’ to ‘cure’.
See Also
What is WuXi AppTec Co Ltd's Pre-Tax Income?
Pre-Tax Income
23.9B
CNY
Based on the financial report for Dec 31, 2025, WuXi AppTec Co Ltd's Pre-Tax Income amounts to 23.9B CNY.
What is WuXi AppTec Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
48%
Over the last year, the Pre-Tax Income growth was 107%. The average annual Pre-Tax Income growth rates for WuXi AppTec Co Ltd have been 31% over the past three years , 48% over the past five years .